Physician profile
Marcus Decarvalho
NPI 1427213727
$8,308.35
in general payments reported to CMS, 2019-2025
32 companies · $919 in 2025
The $919 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $992 · 2021: $1,840 · 2022: $1,640 · 2023: $1,444 · 2024: $737 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,100.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,086.27 | 2019-2022 | |
| Alkermes, INC. | $1,058.06 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $853.86 | 2019-2025 | Trintellix |
| Abbvie INC. | $740.41 | 2021-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $626.83 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $582.21 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Lundbeck LLC | $489.53 | 2020-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $381.59 | 2020-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $366.15 | 2019-2025 | Nuedexta, Rexulti |
| Neos Therapeutics, Lp | $321.22 | 2021-2025 | Adzenys Xr-Odt, Exxua |
| Avanir Pharmaceuticals, INC. | $240.21 | 2019-2022 | |
| Indivior INC. | $184.32 | 2019-2024 | Sublocade |
| Axsome Therapeutics, INC. | $160.88 | 2022-2025 | Auvelity |
| Corium, LLC | $153.63 | 2022-2024 | Azstarys |
| Orexo US, INC. | $115.46 | 2019-2023 | Zubsolv |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $108.75 | 2021-2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $106.79 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.32 | 2020-2024 | Caplyta |
| Bausch Health US, LLC | $99.12 | 2021-2023 | Aplenzin |
| Allergan, INC. | $97.61 | 2019-2020 | |
| Almatica Pharma LLC | $90.60 | 2022-2024 | Loreev Xr, Gralise |
| Supernus Pharmaceuticals, INC. | $82.12 | 2022-2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $80.82 | 2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $42.93 | 2023-2024 | Nuplazid |
| Eisai INC. | $28.78 | 2020-2021 | |
| Tris Pharma INC | $20.09 | 2023 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $20.05 | 2019 | |
| Noven Therapeutics, LLC | $18.97 | 2024 | Xelstrym, Secuado |
| Jazz Pharmaceuticals INC. | $16.24 | 2021 | |
| Shire North American Group INC | $15.95 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.48 | 2019 | |
| Neuronetics, INC. | $6.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Decarvalho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.